Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
P1.01-22 Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC
PaperCitations, authors & open-access status
P1.01-22 Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 0 citations, 2019 year and bronze oa status.
0
Citations
2019
Year
bronze
OA Status